Sanofi’s high-capacity insulin pen wins FDA nod

Sanofi (NYSE:SNY) reported today that its Toujeo Max SoloStar high-capacity insulin pen won FDA approval and will be available in the third quarter of this year.

The new device holds 900 units of long-acting insulin and delivers 160 units/mL of Toujeo insulin glargine in each injection, the insulin-maker touted.

Get the full story at our sister site, Drug Delivery Business News.

The post Sanofi’s high-capacity insulin pen wins FDA nod appeared first on MassDevice.